Clinical Trials in Boston

Showing 8241-8260 of 13,548 trials

Exploration of Parameters of Transcranial Direct Current Stimulation (tDCS) in Chronic Pain

NCT01402960

The purpose of this study is to assess the effects of high-definition transcranial direct current stimulation (HD-tDCS) on subjects with chronic musculoskeletal pain. The investigators hypothesize that subjects will show a decrease in pain symptoms in the active anodal stimulation group when compared to sham stimulation.

Chronic Pain

Spaulding Rehabilitation Hospital18 participantsStarted Apr 2011

Boston, Massachusetts, United States

COMPLETEDPhase 1/2< 1 mile

Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis

NCT03251092

Part 1 of this trial will enroll healthy volunteers into a single ascending dose (SAD), multiple ascending dose (MAD), and Food Effect (FE) treatment groups. The SAD treatment group is comprised of at least 3 ascending dose level cohorts where healthy adult subjects will be randomized to receive a single dose of either PTI-808 or placebo and will be followed for 7 days post dose. A safety review committee (SRC) will convene after the completion of each cohort to evaluate safety and pharmacokinetic (PK) data. Following the conclusion of the respective SAD level dose groups and after sufficient review of study data and approval by the SRC, a second set of healthy adult subjects will participate in an assigned MAD treatment group. The MAD treatment group is comprised of 3 ascending dose level cohorts where subjects will be randomized to receive either PTI-808 or placebo daily for 7 days and will be followed for 7 days after receiving the last dose. Also following the conclusion of the respective SAD level dose groups, healthy adult subjects will participate in the FE treatment group. Part 2 of this will enroll healthy volunteers to assess the safety, tolerability, and PK of PTI 808 co administered with PTI 801 and PTI 428 to HVs with daily dosing for 7 consecutive days. Part 3 will enroll adult subjects with cystic fibrosis (CF) into a MAD treatment group consisting of 2 cohorts. Subjects will receive PTI-808 co-administered with PTI-801 and PTI-428. PTI-808 will be administered daily for 7 consecutive days followed by PTI-808 + PTI-801 + PTI-428 administered daily for 14 consecutive days. Part 4 will enroll adult subjects with cystic fibrosis (CF) into 28-day cohorts. Subjects will receive PTI-808 co-administered with PTI-801 with or without PTI-428 versus matching placebo.

Healthy Volunteer - CompleteCystic Fibrosis - Complete

Proteostasis Therapeutics, Inc.179 participantsStarted Jul 2017

Tucson, Arizona, United States • Stanford, California, United States • Denver, Colorado, United States +45 more locations

Exploration of Parameters of Transcranial Direct Current Stimulation (tDCS) in Chronic Pain

Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis

Find Trials by Condition in Boston

Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)

Patient Navigation to Improve Patient-Centered Cancer Care

Physical Activity and Cognition Study

A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors

Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD

3D Printer Modified CPAP Mask for Obstructive Sleep Apnea

An Observational Study Evaluating the Safety, Tolerability, and Efficacy of Treatment of SM04690 or Placebo Previously Injected in the Target Knee Joint of Subjects With Moderately to Severely Symptomatic Osteoarthritis

A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)

Single-arm, Open-label, Phase II Trial of HD-tDCS in Fibromyalgia Patients

Ambulation as a Factor on Oscillating Thermometry

Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft in AV Graft Patients (AVeVA)

ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

USS Virginia Closed-Loop for Overnight Control in Type 1 Diabetes

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis

A Dose-escalation Study in Subjects With Pulmonary Arterial Hypertension (PAH)

Evaluation of Virtual Touch Tissue Imaging Quantification (VTIQ - 2D-SWE) in the Assessment of BI-RADS® 3 and 4 Lesions

Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus)